Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia

Insomnia Clinical Trial

— EPOCH  

Official title:

Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia: A 6 Week, Multicenter, Randomized, Double -Blind, Placebo-controlled Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00308503
• Other study ID #: EFC6220
• Status: Completed
• Phase: Phase 3
• First received: March 28, 2006
• Last updated: November 29, 2010
• Start date: February 2006
• Est. completion date: August 2007

Study information

• Verified date: November 2010
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationCanada: Ethics Review CommitteeAustralia: Department of Health and Ageing Therapeutic Goods Administration
• Study type: Interventional

Clinical Trial Summary

The aim of the study is to confirm the efficacy of eplivanserin 5mg/day on sleep maintenance of patients with primary insomnia using night polysomnography recordings over a 6-week treatment period corresponding to a stabilization of improvement of sleep.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 608
• Est. completion date: August 2007
• Est. primary completion date: August 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of primary insomnia based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for at least one month preceding the study visit.

• Disturbance of sleep maintenance:

• Based on patient' s information:

• Patient has spent at least 6.5 hours and not more than 9.0 hours, in bed, each night, over the preceding two weeks,

• Patient must complain of at least one hour of wakefulness after sleep onset for at least 3 nights per week over the preceding month,

• Patient must report impact on daytime functioning associated with sleep maintenance insomnia

Inclusion will be based on the nocturnal polysomnography (NPSG) recordings performed at the sleep laboratory during the two screening nights.

Exclusion Criteria:

• Females who are lactating or who are pregnant, or of childbearing potential not using an acceptable form of contraception

• Patients presenting with acute or chronic pain resulting in insomnia

• Patients with current psychiatric disturbances

• Body mass index > 32

• Evidence of any clinically significant, severe or unstable, acute or chronically progressive medical or surgical disorder, or any condition that may interfere with the absorption, metabolism, distribution or excretion of the study drug, or may affect patient safety

• Clinically significant and abnormal electrocardiogram (ECG) (including QTc B > 500ms),

• A positive test for hepatitis B (hepatitis B surface [HBs] antigens) or C (hepatitis C virus [HCV] antibodies)

• Positive qualitative urine drug screen at screening

• Consumption of xanthine-containing beverages (i.e. tea, coffee, or cola) comprising usually more than 5 cups or glasses per day

• Use of any over-the-counter or prescription sleep medication, or of any substance with psychotropic effects or properties known to affect sleep/wake, within one week or five half-lives (whichever is longer), prior to screening

• Night shift workers, and individuals who nap 3 or more times per week over the preceding month

• Based on medical history and/or NPSG:

• primary hypersomnia

• narcolepsy

• breathing-related sleep disorder (apnea-hypopnea index > 10/hour of sleep)

• circadian rhythm sleep disorder

• parasomnia (e.g. somnambulism)

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Insomnia
• Sleep Initiation and Maintenance Disorders

Intervention

Drug:
• eplivanserin (SR46349)
oral administration
• placebo
oral administration

Locations

Country	Name	City	State
Australia	Sanofi-Aventis	Macquarie Park	New South Wales
Canada	Sanofi-Aventis	Laval
United States	Sanofi-Aventis	Bridgewater	New York

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Countries where clinical trial is conducted

United States,  Australia,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline of night polysomnography Wake Time After Sleep Onset (PSG WASO)		week 6	No
Secondary	Change from baseline in general productivity domain of the FOSQ (Functional Outcome of Sleep Questionnaire)		week 6	No
Secondary	Change from baseline in patient reported wake after sleep onset (pr-WASO)		week 6	No